TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors

Journal of Clinical Investigation

Volumn 126, Issue 2, 2016, Pages 784-794

  Doorduijn, Elien M ^a   Sluijter, Marjolein ^a   Querido, Bianca J ^a   Oliveira, Cláudia C ^a   Achour, Adnane ^b   Ossendorp, Ferry ^a   Van Der Burg, Sjoerd H ^a   Van Hall, Thorbald ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SCIENCE FOR LIFE LABORATORY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; L SELECTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; T LYMPHOCYTE RECEPTOR; TAP PROTEIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TRH4 PEPTIDE; TUMOR ANTIGEN; TUMOR PROTEIN; UNCLASSIFIED DRUG; ABC TRANSPORTER; AUTOANTIGEN; EPITOPE; HLA ANTIGEN CLASS 1; TAP1 PROTEIN, MOUSE;

ADOPTIVE IMMUNOTHERAPY; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CANCER CONTROL; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SELECTION; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; THYMOCYTE; THYMUS; TUMOR ESCAPE; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIGEN PEPTIDE TRANSPORTER-1; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; ATP-BINDING CASSETTE TRANSPORTERS; AUTOANTIGENS; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; MICE; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; PEPTIDES; TUMOR ESCAPE;

EID: 84955478152     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI83671     Document Type: Article

References (39)

1. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
2. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480-489.
3. Wolchok JD, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133.
4. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205-214.
5. van der Sluis TC, et al. Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death. Clin Cancer Res. 2015;21(4):781-794.
6. Welters MJ, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A. 2010;107(26):11895-11899.
7. Nobuoka D, Yoshikawa T, Sawada Y, Fujiwara T, Nakatsura T. Peptide vaccines for hepatocellular carcinoma. Hum Vaccin Immunother. 2013;9(1):210-212.
8. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14(2):135-146.
9. Garrido F, Cabrera T, Aptsiauri N. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer. 2010;127(2):249-256.
10. Carretero R, et al. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics. 2008;60(8):439-447.
11. Andersson E, et al. Correlation of HLA-A02∗ genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother. 2012;61(8):1243-1253.
12. Verweij MC, et al. Inhibition of mouse TAP by immune evasion molecules encoded by non-murine herpesviruses. Mol Immunol. 2011;48(6-7):835-845.
13. Oliveira CC, et al. New role of signal peptide peptidase to liberate C-terminal peptides for MHC class I presentation. J Immunol. 2013;191(8):4020-4028.
14. Oliveira CC, Querido B, Sluijter M, Derbinski J, van der Burg SH, van Hall T. Peptide transporter TAP mediates between competing antigen sources generating distinct surface MHC class I peptide repertoires. Eur J Immunol. 2011;41(11):3114-3124.
15. Seidel UJ, Oliveira CC, Lampen MH, Hall T. A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens. Cancer Immunol Immunother. 2012;61(1):119-125.
16. van Hall T, et al. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med. 2006;12(4):417-424.
17. Overwijk WW, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003;198(4):569-580.
18. Clarke SR, Barnden M, Kurts C, Carbone FR, Miller JF, Heath WR. Characterization of the ovalbumin-specific TCR transgenic line OT-I: MHC elements for positive and negative selection. Immunol Cell Biol. 2000;78(2):110-117.
19. Schonrich G, et al. Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell. 1991;65(2):293-304.
20. Ross EM, Bourges D, Hogan TV, Gleeson PA, van Driel IR. Helios defines T cells being driven to tolerance in the periphery and thymus. Eur J Immunol. 2014;44(7):2048-2058.
21. Daley SR, Hu DY, Goodnow CC. Helios marks strongly autoreactive CD4+ T cells in two major waves of thymic deletion distinguished by induction of PD-1 or NF-κB. J Exp Med. 2013;210(2):269-285.
22. Hernandez J, Aung S, Redmond WL, Sherman LA. Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J Exp Med. 2001;194(6):707-717.
23. Miller JF, Kurts C, Allison J, Kosaka H, Carbone F, Heath WR. Induction of peripheral CD8+ T-cell tolerance by cross-presentation of self antigens. Immunol Rev. 1998;165:267-277.
24. Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res. 2011;17(8):2270-2280.
25. Oliveira CC, et al. The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects. J Exp Med. 2010;207(1):207-221.
26. Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med. 2012;209(13):2351-2365.
27. Ardolino M, et al. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest. 2014;124(11):4781-4794.
28. Oliveira CC, van Hall T. Alternative antigen processing for MHC Class I: multiple roads lead to Rome. Front Immunol. 2015;6:298.
29. Palmer DC, et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A. 2008;105(23):8061-8066.
30. Seaman BJ, et al. Audiovestibular dysfunction associated with adoptive cell immunotherapy for melanoma. Otolaryngol Head Neck Surg. 2012;147(4):744-749.
31. Morgan RA, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36(2):133-151.
32. Seliger B. The link between MHC class I abnormalities of tumors, oncogenes, tumor suppressor genes, and transcription factors. J Immunotoxicol. 2014;11(4):308-310.
33. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002;3(11):999-1005.
34. Seliger B, et al. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol Immunother. 2010;59(4):529-540.
35. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol. 2002;12(1):3-13.
36. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res. 2006;12(13):3890-3895.
37. Zhumabekov T, Corbella P, Tolaini M, Kioussis D. Improved version of a human CD2 minigene based vector for T cell-specific expression in transgenic mice. J Immunol Methods. 1995;185(1):133-140.
38. Uchtenhagen H, et al. Proline substitution independently enhances H-2D(b) complex stabilization and TCR recognition of melanoma-associated peptides. Eur J Immunol. 2013;43(11):3051-3060.
39. van Stipdonk MJ, Badia-Martinez D, Sluijter M, Offringa R, van Hall T, Achour A. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res. 2009;69(19):7784-7792.